Press Releases
“A leader in its field” – Interview by Luxembourg Chambre of Commerce
Jul
B Medical Systems welcomed the Luxembourg Chamber of Commerce & Guichet Unique PME at its headquarters in Luxembourg. During the visit, Luc Provost, our CEO granted them an interview.
“What projects are you currently working on?
We are currently working on the launch of more than 60 new patented products of which several are true significant innovations when compared to exiting technologies / products today. In the blood transfusion segment we have launched products which for the first time, allow to completely eliminate human error in certain operations and thus secure constant quality of blood components. In the vaccine world we have launched a solar refrigerator capable of maintaining vaccines within safe temperatures for more than one month even if there is absolutely no sunshine. In the vaccine world this is a revolution and will allow to save many more lives in regions which are subject to long rainy seasons.
What successes are you particularly proud of?
One success I am particularly proud of is to have changed this non-core, multi-disciplinary business of a large group ( Electrolux / Dometic ) into a very focused medtech company who’s focus is to develop, produce and install life-saving solutions all over the globe. In 2015 when we succeeded the management buy-out with the help of Navis Capital Malaysia, it was obvious that delocalization to Asia had been considered and also very thoroughly investigated, but the Luxembourg know how and capacity to innovate was more important than the attractiveness of delocalization to Asia and since 2015, Navis have invested over 17 m€ in modernization and automation of the manufacturing plant of Hosingen to bring it to the highest standards. In just three years, time we have increased our R&D capacity from 4 to 25 FTE’s, we have increased our production capacity of vaccine cold chain products by a multiple of 5 and we are in the process of multiplying our production capacity of medtech products by a multiple of 20. 100% of this through self-financing.”
